Prescribing proton pump inhibitors: is it time to pause and rethink?
about
Management of gastric polyps: an endoscopy-based approachProton pump inhibitor-associated hypomagnesemia: what do FDA data tell us?Proton Pump Inhibitors and the Risk for Fracture at Specific Sites: Data Mining of the FDA Adverse Event Reporting System.Patient-Provider Interactions Affect Symptoms in Gastroesophageal Reflux Disease: A Pilot Randomized, Double-Blind, Placebo-Controlled TrialEffects of proton pump inhibitors and histamine-2 receptor antagonists on response to fidaxomicin or vancomycin in patients with Clostridium difficile-associated diarrhoeaPharmacotherapy of Zollinger-Ellison syndrome.ENETS Consensus Guidelines Update for the Management of Patients with Functional Pancreatic Neuroendocrine Tumors and Non-Functional Pancreatic Neuroendocrine Tumors.Reflux and aerodigestive tract diseases.Current pharmacological management of gastroesophageal reflux disease.Acid-Suppressive Therapy and Risk of Infections: Pros and Cons.Proton pump inhibitors (PPIs) impact on tumour cell survival, metastatic potential and chemotherapy resistance, and affect expression of resistance-relevant miRNAs in esophageal cancer.Use of proton pump inhibitors and mortality after hip fracture in a nationwide study.Long-Term (7 Years) Follow-Up of Roux-en-Y Gastric Bypass on Obese Adolescent Patients (<18 Years).Proton pump inhibitors utilisation in older people in New Zealand from 2005 to 2013.Effective and safe proton pump inhibitor therapy in acid-related diseases - A position paper addressing benefits and potential harms of acid suppressionPotassium-Competitive Acid Blockers (P-CABs): Are They Finally Ready for Prime Time in Acid-Related Disease?Randomised trial of the effect of a gastrin/CCK2 receptor antagonist on esomeprazole-induced hypergastrinaemia: evidence against rebound hyperacidity.
P2860
Q26864650-94867A29-476B-489B-9C76-55BEDDC9C2C3Q30620638-33BC9B23-037B-4709-9779-9CD2E798E0D1Q33912042-CA7B51D2-4F90-467F-97B3-22487BADF50EQ35793789-BD21D9B2-7820-4C1F-ACB1-740263DC6841Q36140398-7591C684-5C79-40B7-8B18-2F568F9D3D85Q36632665-415CF1D8-FFBB-4A30-B0BF-0D3AECF0F0B9Q36849357-563740EE-0212-4211-AB44-945677138B1DQ38024728-4A6E549C-31BA-4231-88F8-4B00E2386344Q38123482-596269D6-A7E8-49B5-BD33-FEDDAA57E930Q38865456-D38E8014-903C-479D-8F01-EA078FF67866Q38961241-20389A91-CBB3-4D8C-B07B-70F5BA7855E3Q39023035-AAE17498-8632-472C-B70F-7397363D6081Q39872078-D49F44C5-4AC2-424B-BBCB-808296FA5BE3Q41132376-7AABE877-8FF6-44B4-B4F6-FF1991962ADDQ42371575-BE450FBE-46DC-457F-A6EC-A2CD876962F7Q42923401-12DC2276-CACF-45E3-9B0C-2D300BA3B8A6Q48263186-E107BE74-676C-434B-BA6C-2345960B05C6
P2860
Prescribing proton pump inhibitors: is it time to pause and rethink?
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Prescribing proton pump inhibitors: is it time to pause and rethink?
@en
Prescribing proton pump inhibitors: is it time to pause and rethink?
@nl
type
label
Prescribing proton pump inhibitors: is it time to pause and rethink?
@en
Prescribing proton pump inhibitors: is it time to pause and rethink?
@nl
prefLabel
Prescribing proton pump inhibitors: is it time to pause and rethink?
@en
Prescribing proton pump inhibitors: is it time to pause and rethink?
@nl
P2860
P1433
P1476
Prescribing proton pump inhibitors: is it time to pause and rethink?
@en
P2093
Nimish Vakil
P2860
P304
P356
10.2165/11599320-000000000-00000
P577
2012-03-01T00:00:00Z
P6179
1049888477